These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1277 related articles for article (PubMed ID: 2146499)

  • 1. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
    N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
    Godsland IF; Crook D; Devenport M; Wynn V
    Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
    Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
    Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary heart disease risk markers in users of low-dose oral contraceptives.
    Godsland IF; Crook D; Wynn V
    J Reprod Med; 1991 Mar; 36(3 Suppl):226-37. PubMed ID: 2046076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel.
    Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R
    Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
    Prasad RN; Liew D; Ratnam SS
    Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study.
    Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C
    Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
    Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L
    Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the metabolic effects of steroidal contraceptives.
    Sondheimer SJ
    Endocrinol Metab Clin North Am; 1991 Dec; 20(4):911-23. PubMed ID: 1778182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic effects of two low-dose triphasic oral contraceptives containing ethinyl estradiol and levonorgestrel or gestodene.
    Lepot MR; Gaspard UJ
    Int J Fertil; 1987; 32 Suppl():15-20. PubMed ID: 2906343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins.
    Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC
    Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pill formulations and their effect on lipid and carbohydrate metabolism.
    Brooks PG
    J Reprod Med; 1984 Jul; 29(7 Suppl):539-46. PubMed ID: 6481707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.
    Skouby SO; Endrikat J; Düsterberg B; Schmidt W; Gerlinger C; Wessel J; Goldstein H; Jespersen J
    Contraception; 2005 Feb; 71(2):111-7. PubMed ID: 15707560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a combined oral contraceptive pill in black Zimbabwean women.
    Kasule J; Mbizvo M; Makuyana D; Masona D
    Cent Afr J Med; 1991 Dec; 37(12):403-9. PubMed ID: 1806254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desogestrel- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins.
    Ylikorkala O; Kuusi T; Tikkanen MJ; Viinikka L
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1238-42. PubMed ID: 2960690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.